Paul Goldenheim, MD
Paul Goldenheim is the chief executive officer of Adenium Biotech and is also currently working as a director and consultant in the field of biotechnology. He is trained as a pulmonary physician and has a long history in pharmaceutical research, development and management, most recently as the president of TransForm Pharmaceuticals (acquired by Johnson & Johnson). He received his Bachelor of Arts in Biochemical Sciences, magna cum laude, from Harvard University and his Doctor of Medicine from Harvard Medical School.
Goldenheim has authored numerous scientific publications and is the inventor of a number of pharmaceutical patents. Furthermore, he serves on the boards of directors of several biotechnology companies, including Alinea Pharmaceuticals and Hydra Biosciences. He was previously the vice-chairman of the board of directors of Hypnion (acquired by Eli Lilly), as well as a member of Promedior and BIND Therapeutics’ boards of directors. Goldenheim also is currently a director of the board of The Big Apple Circus.